Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 17:34:100725.
doi: 10.1016/j.lanwpc.2023.100725. eCollection 2023 May.

Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China

Xuewen Tang  1 , Yanhui Xiao  2 , Xuan Deng  1 , Yang Zhou  1 , Haiping Chen  2 , Rui Yan  1 , Yao Zhu  1 , Shengyi Wang  2 , Hui Wang  3 , Xiujuan Zhu  3 , Linyun Luo  2 , Yan Liu  4 , Zhiying Yin  5 , Guoping Zhang  6 , Zhongbing Chen  7 , Jian Jiang  6 , Xiaoming Yang  2 , Hanqing He  1
Affiliations

Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China

Xuewen Tang et al. Lancet Reg Health West Pac. .

Abstract

Background: Sabin inactivated and bivalent oral poliovirus vaccine (sIPV, bOPV) were commonly used in China since 2016. We conducted an open-label, randomised, controlled phase 4 trial to assess immune persistence following sequential immunisation with sIPV or bOPV, and immunogenicity and safety of a booster dose of poliovirus vaccine in children aged 4 years.

Methods: Participants from a previous clinical trial with three different sequential schedules with sIPV (I) or bOPV (B) at ages 2, 3, and 4 months (Groups I-B-B, I-I-B, I-I-I) in 2017 were followed-up. The children were further divided into five subgroups after sIPV was given for Group I-B-B, and sIPV or bOPV randomly given for Group I-I-B and Group I-I-I (128 children in Groups I-B-B-I, 60 in Group I-I-B-B, 64 in Group I-I-B-I, 68 in Group I-I-I-B, 67 in Group I-I-I-I). Immune persistence and immunogenicity were assessed by measuring poliovirus type-specific antibodies, and safety were analysed in all children who received the booster dose.

Findings: Between Dec 5, 2020 and Jun 30, 2021, we respectively enrolled 381 participants in the immune persistence analysis, and 352 participants in per protocol (PP) analysis of the immunogenicity of the booster immunisation. Seropositivity rates of antibodies against poliovirus types 1 and 3 were all >90% four years after primary immunisation, while for poliovirus type 2 were 46.83%, 75.41%, and 90.23% (χ2 = 60.948, P < 0.001) for Groups I-B-B, I-I-B, and I-I-I, respectively. After the booster dose, seropositivity rates were 100% for all three serotypes in Group I-B-B-I, I-I-B-I and I-I-I-I; In Group I-I-B-B and I-I-I-B, the seropositivity rates for types 1 and 3 were all 100%, for type 2 were 92.59% and 98.46%. The geometric mean titres (GMTs) against poliovirus 1 and 3 were all high in five groups (>1860.73), and the GMTs against type 2 were significantly lower in groups booster with bOPV: Group I-I-B-B (50.60) and Group I-I-I-B (247.84). There was no significant difference in seropositivity rates or GMTs for all three serotypes (P > 0.05) between Group I-I-B-I and I-I-I-I. No serious adverse events occurred during the study.

Interpretation: Our findings suggest that at least two sIPV doses are needed in the current routine poliovirus immunisation schedule, and schedules containing 3 or 4 doses of sIPV provide better protection against poliovirus type 2 than the current sIPV-sIPV-bOPV-bOPV schedule in China.

Funding: Medical and Health Science and Technology of Zhejiang Province (2021KY118). This trial was registered with ClinicalTrials.gov (NCT04576910).

Keywords: Booster dose; Immunogenicity; Persistence immunity; Poliovirus; Sabin strain.

PubMed Disclaimer

Conflict of interest statement

XMY, YHX, HPC, LYL and SYW are employees of the China National Biotec Group Company Limited. HW and XJZ are employees of the Beijing Institute of Biological Products Company Limited. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Trial profile. Enrolled subjects were assigned to one of the two booster vaccination groups. SS = safety set. PPS = Per-protocol dataset. bOPV = bivalent types 1 and 3 oral polio vaccine. sIPV = Sabin strain inactivated polio vaccine.
Fig. 2
Fig. 2
GMTs of antibodies against PV1/PV2/PV3 among three groups with different primary polio vaccination schedules. GMT = geometric mean titre; PV1 = polivirus type 1; PV2 = polivirus type 2; PV3 = polivirus type 3.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Donlan A.N., Petri W.A., Jr. Mucosal immunity and the eradication of polio. Science. 2020;368(6489):362–363. doi: 10.1126/science.abb8588. PMID: 32327582; PMCID: PMC7821416. - DOI - PMC - PubMed
    1. Global Polio Eradication Initiative≥Data and monitoring > Polio this week > Wild poliovirus list [Internet] 2022. https://polioeradication.org/polio-today/polio-now/wild-poliovirus-list/ [cited 2022 May 7]
    1. Manish P., Stephen C. Addressing the challenges and opportunities of the polio endgame: lessons for the future. J Infect Dis. 2017;216(suppl_1):S1. - PMC - PubMed
    1. Patel M., Zipursky S., Orenstein W., et al. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14(5):749–762. - PubMed
    1. Garon J., Seib K., Orenstein W.A., et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016:1–16. - PubMed

Associated data